Bio Medica Laboratories
- Market cap
- ₹ 189 Cr.
- P/E
- 16.7x
- P/B
- 7.35x
- 52-week range
- 101.5 – 181
- ROE
- 45%
- Debt / equity
- 1.51
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE SME
About
Bio Medica Laboratories Ltd is engaged in the manufacturing of pharmaceutical parenteral formulations. The Company manufactures variety of products, comprising ethical drugs, generic drugs and over the-counter drugs (OTC) in the form of injectables namely Liquid injections and dry powder injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a range of medical needs and preferences both domestically as well as exported through merchant exporter. It offers a total of 58 products. Its products include 100 ml Amikacin Sulphate IP Injection, Vitamin B12, D3 & Calcium Gluconolactobionate Injection, 2ml Amikacin Sulphate Injection, Buprenorphine Injection, and 30 ml Amikacin Sulphate Injection. Buprenorphine injection is used as a short-term treatment to relieve severe pain in people who need an opioid pain medication and who cannot be treated with other pain medications.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Bio Medica Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)16.7 against a typical 34.3: cheaper than most peers (1st = cheapest).43rd of 220
- Share price, 3 months−2.3% against a typical −0.5%.109th of 200
- Size₹ 188.6 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).121st of 199
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 2 Sep 2026 | Other business matters | To consider and approve the Notice of 11th Annual General Meeting and to authorize someone to issue the same to all the shareholders and other matters |
| 27 Jul 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 22 Jun 2026 | Other business matters | Prior Intimation of Board Meeting as per Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Mar 2026 |
|---|---|
| Sales | 43 |
| Expenses | 23 |
| Operating Profit | 20 |
| OPM % | 46% |
| Other Income | 0 |
| Interest | 2 |
| Depreciation | 1 |
| Profit before tax | 16 |
| Tax % | 27% |
| Net Profit | 12 |
| EPS in Rs | 13.06 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Bio Medica Laboratories | ₹ 154.90 | ₹ 189 Cr. | 16.7x | 7.4x | 45% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 34.7x | 5x | — | 19.8% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 91.3x | 14.3x | — | 26.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 69.9x | 18.5x | — | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 20.8x | 4.2x | — | 15.7% |
| Laurus Labs | ₹ 1,974.00 | ₹ 1,06,658 Cr. | 123.1x | 20.8x | — | 15% |
Management
- Santosh Kale
- Chief Financial Officer
- Pratiksha Bhandari
- Company Secretary, Compliance Officer
- Pradeep Mehta
- Managing Director, Executive Director
- Mukesh Mehta
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.